1. Introduction {#sec1-marinedrugs-15-00035}
===============

Seven examples of marine bioactive compounds or derivatives were approved by the U.S. Food and Drug Administration or in clinical trials, such as salinosporamide A, plitidepsin, bryostatin 1, cytarabine, vidarabine, eribulin mesylate, and trabectidin (ET-743) \[[@B1-marinedrugs-15-00035]\]. Microorganisms from the mangrove environment produce a multitude of novel and biologically-active natural products \[[@B2-marinedrugs-15-00035],[@B3-marinedrugs-15-00035]\]. According to genomic studies, numerous microorganisms have far greater potential to produce specialized metabolites than was thought from classic bioactivity screens. However, dozens of fungal gene clusters may be silent under standard laboratory growth conditions, which lead to the fact that some secondary metabolites pathways cannot be expressed. Therefore, certain groups of fungi have the potential to produce even more structurally-diverse secondary metabolites if the fungal cryptic biosynthetic pathways are activated \[[@B4-marinedrugs-15-00035]\]. Similar studies were reported for the genomes of filamentous fungi, such as *Aspergillus* spp. \[[@B5-marinedrugs-15-00035]\]. Microbial interspecies competition can have dramatic effects on small molecules, which were produced to defend the habitat or as chemical signals, and may be different from their single-species counterparts \[[@B6-marinedrugs-15-00035],[@B7-marinedrugs-15-00035]\]. Consequently, microorganism co-culture, which is the cultivation of two or more microorganisms in one culture vessel, and a potent way to activate the silent gene clusters and enhance chemical diversity for drug discovery, has aroused great concern in natural product research \[[@B8-marinedrugs-15-00035]\]. A variety of studies have explored the induction of fungal metabolites in fungal and bacterial co-cultures \[[@B9-marinedrugs-15-00035],[@B10-marinedrugs-15-00035],[@B11-marinedrugs-15-00035],[@B12-marinedrugs-15-00035]\], as well as in fungal co-cultures \[[@B13-marinedrugs-15-00035],[@B14-marinedrugs-15-00035],[@B15-marinedrugs-15-00035],[@B16-marinedrugs-15-00035]\].

In continuing the search for novel and bioactive natural products from mangrove endophytic fungi \[[@B17-marinedrugs-15-00035],[@B18-marinedrugs-15-00035],[@B19-marinedrugs-15-00035],[@B20-marinedrugs-15-00035]\], we recently turned to our interest in microorganism co-culture in order to obtain new bioactive compounds. After analyzing the high-performance liquid chromatography (HPLC) profiles of the co-cultivation extracts of 616 strains of mangrove endophytic fungi and *Acinetobacter johnsonii* B2, together with their monoculture extracts, we found that the co-cultivation of *Trichoderma* sp. 307 and *Acinetobacter johnsonii* B2 led to the production of different metabolites to those produced in pure-cultivating of fungal and bacterial controls ([Figure 1](#marinedrugs-15-00035-f001){ref-type="fig"}). As a result, we have discovered two new furan-type isoeremophilane sesquiterpenes (**1**--**2**), three new de-*O*-methyllasiodiplodins (**4**--**6**, including one new natural product), along with twelve known molecules (**3**, **7**--**17**). Herein, the isolation, structure elucidation, biological evaluation, and a brief discussion on the structure--activity relationship (SAR) of compounds **1**--**17** are reported.

2. Results and Discussion {#sec2-marinedrugs-15-00035}
=========================

The mangrove endophytic fungus *Trichoderma* sp. 307 was co-cultured with an aquatic pathogenic bacterium named *Acinetobacter johnsonii* B2 on solid rice medium at 28 °C for 29 days. The CHCl~3~ extract of the fermentation was repeatedly fractionated and purified to obtain compounds **1**--**17** ([Figure 2](#marinedrugs-15-00035-f002){ref-type="fig"}).

Compound **1** (1.8 mg) was obtained as a white powder. Its molecular formula C~15~H~20~O~4~ was deduced from the high resolution electrospray ionization mass spectroscopy (HRESIMS) peak at *m*/*z* 265.1438 \[M + H\]^+^ (calculated for C~15~H~21~O~4~, 265.1434), implying six degrees of unsaturation. The infrared radiation (IR) spectrum suggested the presence of hydroxy (3175 and 3355 cm^−1^) and conjugated carbonyl (1665 cm^−1^) groups. The ^13^C nuclear magnetic resonance (NMR) and distortionless enhancement by polarization transfer (DEPT) spectroscopic data ([Table 1](#marinedrugs-15-00035-t001){ref-type="table"}) revealed carbon signals for three methyl groups (δ~C~ 28.0, 14.8, and 9.2), two methylenes (δ~C~ 71.8 and 34.6), five methines (δ~C~ 146.6, 135.3, 126.3, 55.0, and 43.9), and five quaternary carbons, including one carbonyl group (δ~C~ 206.8), one ketal carbon (δ~C~ 100.5), one oxygenated carbon (δ~C~ 77.8), and two quaternary carbons (δ~C~ 139.4 and 39.9). The presence of one carbonyl group and two double bonds was attributable to three degrees of unsaturation, and the remaining three degrees of unsaturation indicated the existence of the tricyclic ring system in **1**. The ^1^H NMR and heteronuclear single-quantum correlation (HSQC) spectra of **1** ([Table 1](#marinedrugs-15-00035-t001){ref-type="table"}) displayed signals for three methyls \[δ~H~ 1.35 (H-15, s); 1.01 (H-13, d, *J* = 7.2 Hz); 0.95 (H-14, d, *J* = 7.3 Hz)\], one oxygen-bearing methylene \[δ~H~ 4.07 (H-12a, dd, *J* = 8.8, 8.3 Hz); 3.34 (H-12b, dd, *J* = 8.8, 6.4 Hz)\], one methylene \[δ~H~ 1.79 (H-6a, d, *J* = 14.1 Hz); 1.44 (H-6b, d, *J* = 14.1 Hz)\], three olefinic methines \[δ~H~ 7.04 (H-1, d, *J* = 9.8 Hz); 6.10 (H-9, s); 5.84 (H-2, d, *J* = 9.8 Hz)\], and two methine groups \[δ~H~ 2.58 (H-11, ddq, *J* = 8.3, 7.2, 6.4 Hz); 2.24 (H-4, q, *J* = 7.3 Hz)\].

According to the ^1^H-^1^H correlation spectroscopy (COSY) spectrum, there were three independent spin systems of H-1/H-2, H-4/H-14, and H-12/H-11/H-13 ([Figure 3](#marinedrugs-15-00035-f003){ref-type="fig"}). The ultra violet (UV) maximum at 284 nm revealed that the carbonyl group (δ~C~ 206.8, C-3) and the double bonds (δ~C~ 146.6, C-1; 126.3, C-2) were conjugated, which was confirmed by the heteronuclear multiple bond correlation (HMBC) correlations from olefinic protons H-1, and H-2 to C-3. The observed HMBC correlations ([Figure 3](#marinedrugs-15-00035-f003){ref-type="fig"}) from H-1 to C-5, from H-2 to C-10, from H-6 to C-5 and C-8, from H-9 to C-1, C-5, and C-7, from H-14 to C-3, C-4, and C-5, and from H-15 to C-5, C-6, and C-10 illustrated the existence of a naphthalenone moiety with two methyl groups at C-4 and C-5, respectively. In addition, the HMBC correlations from H-11 to C-12 and C-13, H-12 to C-8, as well as H-13 to C-7, C-11, and C-12 were observed, which indicated the presence of a furan ring. As evidenced by the ^13^C NMR chemical shift (δ~C~ 100.5), C-8 was determined to be a hemiacetal carbon and was further connected to C-12 via the oxygen atom, which revealed the presence of a furan hemiacetal moiety. In the light of the NMR data (δ~C~ 77.8, C-7), the position of another hydroxyl group was assigned at C-7. Therefore, the planar structure of **1** was established.

The relative configuration of **1** was established by nuclear Overhauser enhancement spectroscopy (NOESY) experiment ([Figure 3](#marinedrugs-15-00035-f003){ref-type="fig"}). The NOESY correlations of H-15 with H-4 and H-6a, and of H-6b with H-13 and H-14, revealed that H-4, H-6a, and H-15 were on the same plane of the ring system, whereas H-13 and H-14 were on the opposite side. The absolute configurations of the 7,8-diol moieties were determined by Snatzke's method \[[@B21-marinedrugs-15-00035],[@B22-marinedrugs-15-00035],[@B23-marinedrugs-15-00035]\]. Negative Cotton effects at 310 and 400 nm in the Mo~2~(AcO)~4~-induced circular dichroism (CD) spectrum ([Figure 4](#marinedrugs-15-00035-f004){ref-type="fig"}) suggested the 7*R* and 8*S* configurations. To support the above deduction, the theoretical electronic circular dichroism (ECD) spectrum was calculated. The calculated ECD spectrum of **1** matched well with the experimental one ([Figure 5](#marinedrugs-15-00035-f005){ref-type="fig"}), which indicated the (4*S*, 5*R*, 7*R*, 8*S*, 11*S*)-configuration of **1**. Thus, compound **1** was a new furan-type isoeremophilane sesquiterpene, for which we suggest the trivial name microsphaeropsisin B.

Compound **2** (3 mg) was obtained as a white powder. The molecular formula was C~15~H~20~O~4~, corresponding to six degrees of unsaturation, based on the HRESIMS peak at *m*/*z* 265.1437 \[M + H\]^+^ (calculated for C~15~H~21~O~4~, 265.1434). The IR spectrum indicated the presence of hydroxy (3185 and 3365 cm^−1^) and conjugated carbonyl (1670 cm^−1^) groups. The ^1^H and ^13^C NMR spectra together with HSQC correlations of **2** revealed the signals for one carbonyl group (δ~C~ 203.4), one ketal carbon (δ~C~ 100.3), one oxygenated carbon (δ~C~ 77.6), two quaternary carbons (δ~C~ 142.4 and 40.4), five methines (δ~C~ 146.1, 132.2, 128.4, 54.4 and 43.9), two methylenes (δ~C~ 71.6 and 38.9), and three methyl groups (δ~C~ 20.9, 9.2 and 7.5). A detailed comparison of the NMR data with those for compound **1** showed the presence of the same furan-type isoeremophilane sesquiterpene framework, except for the different chemical shifts of H-6, H-14, H-15, and C-6, C-10, C-14, and C-15 ([Table 1](#marinedrugs-15-00035-t001){ref-type="table"}). The deduction was supported by the COSY correlations from H-1 to H-2, from H-4 to H-14 and from H-11 to H-12 and H-13, along with the observed HMBC correlations from H-1 to C-3, C-5, C-9, and C-10, from H-2 to C-4 and C-10, from H-4 to C-3, C-6, C-10, and C-14, from H-6 to C-5, C-7, C-8, C-10 and C-15, from H-9 to C-1, C-5, and C-7, from H-11 to C-7, from H-12 to C-8 and C-11, from H-13 to C-7, C-11, and C-12, from H-14 to C-3, C-4, and C-5, as well as from H-15 to C-4, C-6, and C-10 ([Figure 3](#marinedrugs-15-00035-f003){ref-type="fig"}). In addition, compound **2** and **1** had the same mass unit. Thus, we tentatively supposed that compounds **1** and **2** were a pair of epimers, which was confirmed by the increase of chemical shifts for C-6 and C-10, and the decrease of chemical shifts for C-14 and C-15, as well as the NOESY spectroscopic data analysis. The NOESY correlations of H-6a with H-15, and of H-15 with H-14 ([Figure 3](#marinedrugs-15-00035-f003){ref-type="fig"}) suggested their *syn*-orientation, whereas the correlation of H-6b with H-4 and H-13 indicated these two protons were on the opposite face of the molecule. The absolute configurations of the 7,8-diol groups in **2** was also established by Snatzke's method. In the Mo~2~(AcO)~4~-induced CD spectrum ([Figure 4](#marinedrugs-15-00035-f004){ref-type="fig"}), negative Cotton effects at 309 and 398 nm supported the 7*R* and 8*S* configurations. According to a comparison of the calculated ECD spectrum with the experimental data ([Figure 5](#marinedrugs-15-00035-f005){ref-type="fig"}), the absolute configuration of **2** was assigned as 4*R*, 5*R*, 7*R*, 8*S*, 11*S*. Therefore, the gross structure of **2** was identified as shown, named as microsphaeropsisin C.

Compound **4** (2.3 mg) was obtained as a white powder and gave a molecular formula of C~16~H~22~O~5~ by HRESIMS (*m*/*z* 293.1389 \[M − H\]^−^, calculated for C~16~H~21~O~5~, 293.1389), with six degrees of unsaturation. The ^1^H and ^13^C NMR spectra of **4** were similar to those of de-*O*-methyllasiodiplodin \[[@B24-marinedrugs-15-00035]\], which suggested that compound **4** was a de-*O*-methyllasiodiplodin analogue. The major difference in the ^1^H NMR spectrum of **4** in comparison with that of de-*O*-methyllasiodiplodin was the presence of an oxygenated methine proton for H-7 that was shifted downfield to δ~H~ 4.27 (rather than one methylene protons at δ~H~ 1.42 and 1.60 in de-*O*-methyllasiodiplodin). The downfield shifts observed for C-7 in the ^13^C NMR spectrum also indicated the presence of a hydroxy group at C-7 (δ~C~ 68.0) in **4** instead of a methylene group at C-7 (δ~C~ 21.1) in de-*O*-methyllasiodiplodin. The position of the hydroxyl group at C-7 in **4** was further supported on the basis of COSY correlations from H-3 to H-4 and H-17, from H-6 to H-7 and from H-9 to H-10, along with HMBC correlations from H-4 to C-17, from H-5 to C-4, C-6 and C-17, from H-6 to C-7, from H-7 to C-6, from H-8 to C-9, and from H9 to C-6, C-7 and C-8 ([Figure 6](#marinedrugs-15-00035-f006){ref-type="fig"}). In order to determine the absolute configuration of **4**, the theoretical ECD spectrum was calculated. As a result, the calculated curve of (3*R*, 7*R*)-**4** matched well with the experimental one ([Figure 7](#marinedrugs-15-00035-f007){ref-type="fig"}). Hence, the structure of **4** was assigned as (3*R*, 7*R*)-7-hydroxy-de-*O*-methyllasiodiplodin.

Compound **5** (2.3 mg) was obtained as a white powder with specific optical rotation of ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20.0} + 20.0$ (*c* 0.025, MeOH). Its molecular formula was determined as C~16~H~20~O~5~ based on HRESIMS (*m*/*z* 291.1232 \[M − H\]^−^, calculated for C~16~H~19~O~5~, 291.1232), with seven degrees of unsaturation. Its ^1^H NMR and ^13^C NMR data ([Table 2](#marinedrugs-15-00035-t002){ref-type="table"}) bore good resemblance to those of 5-oxolasiodiplodin \[[@B25-marinedrugs-15-00035]\], except for the presence of a chelated hydroxyl proton (δ~H~ 11.97) and the absence of the ^1^H and ^13^C signals of the methoxy group (δ~H/C~ 3.75/55.7) in **5**. Accordingly, the structure of **5** was proposed as 5-oxo-de-*O*-methyllasiodiplodin, which was confirmed by the HMBC correlations ([Figure 6](#marinedrugs-15-00035-f006){ref-type="fig"}) from the chelated hydroxyl proton 15-OH to C-15. The absolute configuration at C-3 was determined as 3*R* by comparing the calculated ECD spectrum with the experimental one. As a result, the experimental ECD spectrum of **5** showed excellent accordance with (3*R*)-**5** ([Figure 7](#marinedrugs-15-00035-f007){ref-type="fig"}). Thus, the structure and absolute configuration of **5** were identified as shown in [Figure 1](#marinedrugs-15-00035-f001){ref-type="fig"}, named as (3*R*)-5-oxo-de-*O*-methyllasiodiplodin.

Compound **6** (2.6 mg) was isolated as colorless needles, and its molecular formula was determined to be C~16~H~20~O~5~ with seven degrees of unsaturation. Comparison of the 1D NMR data of **6** ([Table 2](#marinedrugs-15-00035-t002){ref-type="table"}) with those of **5** showed close similarity with some minor variations for the chemical shifts of C-3 through C-9, along with the change from the methylene group C-7 in de-*O*-methyllasiodiplodin to a carbonyl group at δ~C~ 211.4 in **6**. It was deduced that the position of the ketone carbonyl in the alkyl ring was changed. The deduction was supported by HMBC correlations from H-5, H-6, and H-8 to the ketone carbonyl C-7 (δ~C~ 211.4) ([Figure 6](#marinedrugs-15-00035-f006){ref-type="fig"}). The 3*R*-configuration of **6** was determined by the comparison of the calculated ECD spectrum with the experimental one ([Figure 7](#marinedrugs-15-00035-f007){ref-type="fig"}). To the best of our knowledge, compound **6** is reported here as a new natural product and was named as (3*R*)-7-oxo-de-*O*-methyllasiodiplodin.

The structures of compounds **3**, **7**--**17** were assigned by comparison of their spectroscopic data (1D and 2D NMR, MS) and optical rotations with published values. Therefore, the known compounds **3**, **7**--**17** were identified as microsphaeropsisin (**3**) (3.2 mg) \[[@B26-marinedrugs-15-00035]\], (3*R*)-5-oxolasiodiplodin (**7**) (67.9 mg) \[[@B25-marinedrugs-15-00035]\], (3*S*)-6-oxo-de-*O*-methyllasiodiplodin (**8**) (3.8 mg) \[[@B27-marinedrugs-15-00035]\], (3*R*)-de-*O*-methyllasiodiplodin (**9**) (74.3 mg) \[[@B24-marinedrugs-15-00035]\], (3*R*,4*R*)-4-hydroxy-de-*O*-methyllasiodiplodin (**10**) (71.8 mg) \[[@B28-marinedrugs-15-00035]\], (3*R*,5*R*)-5-hydroxy-de-*O*-methyllasiodiplodin (**11**) (93.1 mg) \[[@B29-marinedrugs-15-00035]\], (3*R*,6*R*)-6-hydroxy-de-*O*-methyllasiodiplodin (**12**) (3.5 mg) \[[@B29-marinedrugs-15-00035]\], (3*R*)-lasiodiplodin (**13**) (29 mg) \[[@B30-marinedrugs-15-00035]\], (3*S*)-ozoroalide (**14**) (15 mg) \[[@B31-marinedrugs-15-00035]\], (3*S*,5*R*)-5-hydroxylasiodiplodin (**15**) (16.8 mg) \[[@B25-marinedrugs-15-00035]\], (*E*)-9-etheno-lasiodiplodin (**16**) (15.9 mg) \[[@B27-marinedrugs-15-00035]\], and (3*R*)-nordinone (**17**) (18 mg) \[[@B32-marinedrugs-15-00035]\], respectively.

α-Glucosidase inhibitors are helpful to prevent deterioration of Type 2 diabetes and for the treatment of the disease in the early stage, which can delay the liberation of glucose from food and retard glucose absorption, thus lowering the postprandial blood glucose level \[[@B33-marinedrugs-15-00035]\]. Some lasiodiplodins with α-glucosidase inhibitory activity had been reported \[[@B34-marinedrugs-15-00035]\], so the α-glucosidase inhibitory effects of the isolated compounds were evaluated. As a result ([Table 3](#marinedrugs-15-00035-t003){ref-type="table"}), compounds **4**, **5**, **8**, **9**, and **10** exhibited potent α-glucosidase inhibitory activity with IC~50~ of 25.8, 54.6, 64.2, 48.9, and 60.3 µM, respectively, which were much better than acarbose (IC~50~ of 703.8 µM) as a positive control. Compounds **16** and **17** revealed seven-fold better inhibitory effects (IC~50~ of 101.3 and 105.7 μM, respectively) than acarbose. Compounds **2**, **6**, **7**, and **14** showed moderate inhibitory activity against α-glucosidase with IC~50~ values of 188.7, 178.5, 176.8, and 198.1 μM, respectively. The other molecules were inactive with IC~50~ values more than 200 μM. The results indicated that the configuration at C-5 in compounds **1** and **2** might affect α-glucosidase inhibitory activity. Moreover, the methoxy group at C-15 in the lasiodiplodin derivatives decreased the activity (**5** vs. **7** and **9** vs. **13**). For compounds **4**, **10**, **11**, and **12**, compounds **4** and **10** showed potent α-glucosidase inhibitory effects, whereas **11** and **12** were inactive, which attested that the position of the hydroxyl group had a significant impact on the activity. Similarly, according to the different activities of compounds **5**, **6**, and **8**, the position of the carbonyl moiety also exercised a great influence on the α-glucosidase inhibitory effects. In addition, the C-9-C-10 double bond of compound **16** was essential for the activity (**13** vs. **16**).

All isolates were also evaluated for their cytotoxic activity against rat pituitary adenoma GH3 cell lines and rat prolactinoma MMQ cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2*H*-tetrazolium bromide (MTT) method. Compound **9** exhibited more potent cytotoxicity against GH3 and MMQ cell lines with IC~50~ values of 6.44 and 6.58 μM, respectively, while the cytotoxicity against rat normal pituitary cells (RPC) as positive control with IC~50~ of 6.94 µM. Compound **17** displayed moderate cytotoxicity with IC~50~ values of 12.33 and 10.13 μM, respectively, which was ten-fold better than RPC cell lines with an IC~50~ value of 100.03 μM. Compound **8** was less active with IC~50~ values of 21.42 and 13.59 μM, respectively, which was seven-fold better than RPC cells with IC~50~ of 142.8 µM as positive control. However, the rest of compounds showed no cytotoxicity against the two cell lines with IC~50~ values more than 50 μM. The above consequences revealed that methylation of 13-OH or 15-OH in lasiodiplodins resulted in diminished cytotoxicity and some compounds had selective activity against rat normal cells and cancer cells. Moreover, the position of the carbonyl group and hydroxyl moiety might play a significant role in the cytotoxicity. The SAR analysis was also confirmed by our previous studies \[[@B35-marinedrugs-15-00035],[@B36-marinedrugs-15-00035]\].

3. Materials and Methods {#sec3-marinedrugs-15-00035}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-15-00035}
------------------------------------

Optical rotations were recorded using MCP 200 Polarimeter (Anton Paar GmbH, Graz, Austria). Optical density (OD) values were read on a Multiskan Spectrum Microplate Reader (Thermo Scientific Inc., Shanghai, China). CD spectra were acquired on a Chirascan Spectrometer (Applied Photophysics Ltd., Surrey, UK). IR spectra were carried out on a Nicolet Nexus 670 spectrophotometer, in KBr discs. NMR spectra were obtained on a Bruker AVANCE 400 (Bruker Co. Ltd., Zurich, Switzerland). Thin-layer chromatography (TLC) was carried out on pre-coated silica gel GF-254 plates (Qingdao Haiyang Chemical Co., Ltd., Qingdao, China) and column chromatography (CC) was performed over silica gel (Qingdao Haiyang Chemical Co., Ltd., Qingdao, China, 200--300 mesh) on a Sephadex LH-20 (GE healthcare, Buckinghamshire, UK). Semi-preparative HPLC was performed on a Waters 1525 system using a semi-preparative Ultimate XB-C18 column (5 μm, 21.2 mm × 250 mm; Welch) coupled with a Waters 2998 photodiode array detector (Waters Corp., Milford, MA, USA). ESIMS data were measured on a Thermo LCQ DECA XP plus mass spectrometer (Thermo Scientific, Waltham, MA, USA). All reagents and solvents were of commercial quality.

3.2. Fungal and Bacterial Material {#sec3dot2-marinedrugs-15-00035}
----------------------------------

Strain 307, identified as *Trichoderma* sp. (GenBank accession number: KX816009), was isolated from the stem bark of *Clerodendrum inerme*, collected in Zhanjiang Mangrove National Nature Reserve in Guangdong Province, China. A voucher specimen (registration number: 307) has been deposited at the Institute of Marine Biological Natural Products, School of Marine Sciences, Sun Yat-sen University, China.

Bacterium B2, identified as *Acinetobacter johnsonii* (GenBank accession number: KY077679), was isolated from an aquaculture pond at the Maoming Experimental Station in Guangdong (Guanli Marine Organisms LLC.). A voucher specimen (registration number: B2) has been deposited at the Institute of Marine Biological Natural Products, School of Marine Sciences, Sun Yat-sen University, China.

3.3. Co-Cultivation, Extraction, and Isolation {#sec3dot3-marinedrugs-15-00035}
----------------------------------------------

Strain 307 was cultured for one week at 28 °C in five Petri dishes (i.d. 90 mm) containing 25 mL of potato dextrose agar medium. In order to obtain the mycelial suspension, the agar-supporting mycelia were cut and transferred to two 1000 mL Erlenmeyer flasks containing 500 mL of potato dextrose broth and then incubated at 28 °C for four days on a rotary shaker at 150 rpm. The bacterium B2 was cultured in a 1000 mL Erlenmeyer flask containing 500 mL of lysogeny broth at 37 °C for 24 h on a rotary shaker at 150 rpm. Then, 5 mL of the fungal seed broth and 1 mL of the bacterial seed broth were added into rice medium (94 bottles of 1000 mL Erlenmeyer flasks, each containing 50 g of rice, 100 mL distilled water), and incubated at 28 °C for 28 days under static conditions and daylight. Following incubation, the mycelia and solid rice medium were extracted three times with MeOH. The MeOH solution was concentrated under reduced pressure to afford the MeOH solution, which was extracted three times with CHCl~3~ to give 42.6 g of crude extract. The extract was then separated into 11 fractions (Fr. 1--Fr. 11) by column chromatography over silica gel eluted by a gradient of petroleum ether/EtOAc from 100:0 to 0:100 and EtOAc/MeOH from 100:0 to 0:100. Fr. 2 (319.4 mg) was applied to Sephadex LH-20 (CH~2~Cl~2~/MeOH *v*/*v*, 1:1) to yield compound **9** (74.3 mg). Fr. 3 (1355.1 mg) was divided into six fractions (Fr. 3.1 to Fr. 3.6) by CC over silica gel eluting with CHCl~3~/MeOH (*v*/*v*, 99:1), and afforded compound **14** (15 mg). Fr. 3.2 (232.1 mg) was further purified by semipreparative HPLC with 70% MeOH-H~2~O to obtain **17** (18 mg). Fr. 3.3 (301 mg) was subsequently separated on aSephadex LH-20 CC and eluted with CH~2~Cl~2~/MeOH (*v*/*v*, 1:1) to yield **13** (29 mg). Fr. 3.4 (428.2 mg) was chromatographed on silica gel (petroleum ether/EtOAc *v*/*v*, 2:8) to give subfraction Fr. 3.4.5, which was further purified by HPLC with 60% CH~3~CN-H~2~O to afford **5** (2.3 mg), and **16** (15.9 mg). Fr. 3.5 (12 mg) was separated by HPLC with 75% MeOH-H~2~O for **8** (3.8 mg) and **6** (2.6 mg). Fr. 3.6 (203.5 mg) was fractionated on a Sephadex LH-20 CC (CH~2~Cl~2~/MeOH *v*/*v*, 1:1) and further purified using HPLC eluted with 75% MeOH-H~2~O to give **10** (71.8 mg). Fr. 4 (651 mg) was applied to the Sephadex LH-20 CC eluted with CH~2~Cl~2~/MeOH (*v*/*v*, 1:1) to give subfractions Fr. 4.1 and Fr. 4.2. Fr. 4.1 (401.8 mg) was then purified by HPLC (70% MeOH-H~2~O) to yield **7** (67.9 mg). Fr. 4.2 (160.9 mg) was further purified using HPLC with 68% MeOH-H~2~O to obtain **11** (93.1 mg). Fr. 5 (463.2 mg) was subjected to silica gel CC, eluted with petroleum ether/EtOAc (*v*/*v*, 100:0 to 0:100), to obtain subfractions Fr. 5.1-6. Fr. 5.4 (52.1 mg) was purified by HPLC with 60% MeOH-H~2~O to yield **12** (3.5 mg) and Fr. 5.4.1 (11.7 mg), which was further purified using HPLC (75% MeOH-H~2~O) to obtain **3** (3.2 mg). Fr. 5.5 (72.6 mg) was purified by repeated HPLC with 70% MeOH-H~2~O to yield **4** (2.3 mg). Fr. 6 (113.9 mg) was separated into three subfractions (Fr. 6.1-3) by silica gel CC using a stepwise gradient eluting with mixtures of petroleum ether/EtOAc (*v*/*v*, 100:0 to 0:100). Fr. 6.2 (38.9 mg) was subsequently purified by HPLC eluting with 60% MeOH-H~2~O to give **1** (1.8 mg) and **15** (16.8 mg). Fr. 6.3 (50.2 mg) was purified by HPLC (60% MeOH-H~2~O) to yield 3 mg of **2**.

Microsphaeropsisin B (**1**), white powder; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20.0} - 16.0$ (*c* 0.100, MeOH); UV (MeOH) λ~max~ (log ε) 284 (3.69) nm; ECD (MeOH) λ~max~ (Δε) 203 (−18.7), 222 (1.9), 240 (−4.6), 290 (13.7), 352 (−6.3) nm; IR (KBr) λ~max~ 3355, 3175, 1665 cm^−1^; ^1^H NMR (400 MHz, MeOH-*d*~4~) and ^13^CNMR (100 MHz, MeOH-*d*~4~) see [Table 1](#marinedrugs-15-00035-t001){ref-type="table"}; ESIMS *m*/*z* 265.1 \[M + H\]^+^; HRESIMS *m*/*z* 265.1438 \[M + H\]^+^ (calculated for C~15~H~21~O~4~, 265.1434).

Microsphaeropsisin C (**2**), white powder; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20.0} - 124.0$ (*c* 0.025, MeOH); UV (MeOH) λ~max~ (log ε) 283 (3.79) nm; ECD (MeOH) λ~max~ (Δε) 206 (−18.7), 225 (2.7), 240 (−0.8), 288 (21.1), 353 (−8.3) nm; IR (KBr) λ~max~ 3365, 3185, 1670 cm^−1^; ^1^H NMR (400 MHz, MeOH-*d*~4~) and ^13^C NMR (100 MHz, MeOH-*d*~4~) see [Table 1](#marinedrugs-15-00035-t001){ref-type="table"}; ESIMS *m*/*z* 263.1 \[M − H\]^−^; HRESIMS *m*/*z* 265.1437 \[M + H\]^+^ (calculated for C~15~H~21~O~4~, 265.1434).

(3*R*, 7*R*)-7-hydroxy-de-*O*-methyllasiodiplodin (**4**), white powder; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20.0} + 6.06$ (*c* 0.033, MeOH); ECD (MeOH) λ~max~ (Δε) 228 (0.9), 238 (1.9), 292 (−6.7) nm; ^1^H NMR (400 MHz, pyridine-*d*~5~) and ^13^C NMR (100 MHz, pyridine-*d*~5~) see [Table 2](#marinedrugs-15-00035-t002){ref-type="table"}; ESIMS *m*/*z* 293.0 \[M − H\]^−^; HRESIMS *m*/*z* 293.1389 \[M − H\]^−^, calculated for C~16~H~21~O~5~, 293.1389).

(3*R*)-5-oxo-de-*O*-methyllasiodiplodin (**5**), white powder; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20.0} + 20.0$ (*c* 0.025, MeOH); ECD (MeOH) λ~max~ (Δε) 207 (−3.6), 219 (−5.8), 260 (13.7) nm; ^1^H NMR (400 MHz, CDCl~3~) and ^13^C NMR (100 MHz, CDCl~3~) see [Table 2](#marinedrugs-15-00035-t002){ref-type="table"}; HRESIMS *m*/*z* 291.1232 \[M − H\]^−^, calculated for C~16~H~19~O~5~, 291.1232).

(3*R*)-7-oxo-de-*O*-methyllasiodiplodin (**6**), colorless needles; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20.0} + 160$ (*c* 0.020, CHCl~3~); ECD (MeOH) λ~max~ (Δε) 223 (−5.3), 263 (9.7) nm; ^1^H NMR (400 MHz, CDCl~3~) and ^13^C NMR (100 MHz, CDCl~3~) see [Table 2](#marinedrugs-15-00035-t002){ref-type="table"}; HRESIMS *m*/*z* 291.1231 \[M − H\]^−^, calculated for C~16~H~19~O~5~, 291.1232).

3.4. Calculation of ECD Spectra {#sec3dot4-marinedrugs-15-00035}
-------------------------------

The molecular Dreiding force field was run with Spartan 14 software (Wavefunction Inc., Irvine, CA, USA). The time-dependent density functional theory (TDDFT) calculations were carried out with Gaussian 05 (Gaussian, Wallingford, CT, USA). The energy-minimized conformers were generated and optimized at the B3LYP/6-31G (d) level. The integral equation formalism variant polarizable continuum model (IEF-PCM) solvent model for MeOH was used. The ECD spectra were calculated at the RB3LYP/6-311++G (2d, p) level by SpecDis 3.0 (University of Würzburg, Würzburg, Germany) and OriginPro 8.5 (OriginLab, Ltd., Northampton, MA, USA) based on the final optimized structures. All calculations were performed by the high-performance grid computing platform at Sun Yat-Sen University.

3.5. α-Glucosidase Inhibitory Activity Assay {#sec3dot5-marinedrugs-15-00035}
--------------------------------------------

The assay of α-glucosidase inhibitory activity was carried out according to the reported method, with minor modifications \[[@B33-marinedrugs-15-00035]\]. All of the assays were performed under 0.01 M potassium phosphate buffer (pH 7). Enzyme solutions were prepared to give 2.0 Units/mL in 2 mL buffer solution. Test samples were dissolved in dimethyl sulphoxide (DMSO) to give an initial concentration of 4000 μM/L. One-hundred fifty-five microliters of phosphate buffer, 10 μL of test samples, and 10 μL of diluted enzyme solution were mixed in each well of a 96-well microtiter plate. After 20 min incubation at 37 °C, 25 μL of substrate (*p*-nitrophenyl-α-[d]{.smallcaps}-glucopyranoside, 1.5 mg/mL) was added to each well to begin the enzymatic reaction. The reaction was monitored spectrophotometrically by measuring the absorbance at 410 nm for a 1 min interval. Acarbose was used as a positive control. Calculations were performed according to the following equation: the inhibition rates (%) = \[(*B* − *S*)/*B*\] × 100% (*B* represents the OD value in the assay medium with DMSO, *S* represents the OD value in the assay medium with test samples or acarbose). All measurements were done in triplicate from two independent experiments. The reported IC~50~ was the average value of two independent experiments.

3.6. Cytotoxicity Assay {#sec3dot6-marinedrugs-15-00035}
-----------------------

The cytotoxic activities against rat pituitary adenoma MMQ and GH3 cell lines were evaluated by MTT assay following the previous process \[[@B36-marinedrugs-15-00035],[@B37-marinedrugs-15-00035]\]. Briefly, MMQ and GH3 cell lines were seeded in 96-well plates (Corning, New York, NY, USA) at a density of 5 × 10^4^ cells per well. Then, 10 μL of MTT reagent was added to each well and incubated at 37 °C with 5% CO~2~ for 4 h. Subsequently, 100 μL of acidified isopropyl alcohol was added. Then the OD value was measured at 450 nm using a microplate reader and the cell proliferation rate relative to the control was calculated. The IC~50~ was analyzed by SPSS 13.0 (SPSS, Chicago, IL, USA). Rat normal pituitary cells were used as a positive control.

3.7. HPLC Profiles Conditions {#sec3dot7-marinedrugs-15-00035}
-----------------------------

The detection was operated on a Waters 1525 system coupled with a Waters 2998 photodiode array detector (Waters Corp., Milford, MA, USA). The samples were eluted from an analytical Ultimate XB-C18 column (5 μm, 4.6 × 250 mm; Welch) at a flow rate of 1.0 mL/min using the following binary gradient with solvent A consisting of 15% acetonitrile/85% H~2~O and solvent B consisting of 15% H~2~O/85% acetonitrile: 0--22 min, 100%A--100%B; 22--27 min, 100%B; 27--35 min, 100%B--100%A. The detection wavelength was from 200 to 700 nm. The temperature was maintained at 25 °C, and the injection volume was 30 µL.

4. Conclusions {#sec4-marinedrugs-15-00035}
==============

A chemical investigation of the co-cultivation of *Trichoderma* sp. 307 and *Acinetobacter johnsonii* B2 led to the isolation of two new sesquiterpenes (**1**--**2**), two new de-*O*-methyllasiodiplodins (**4**--**5**), one new natural product (**6**), along with twelve known molecules (**3**, **7**--**17**). To the best of our knowledge, compounds **1** and **2** were two unusual furan-type isoeremophilane sesquiterpenes. It is reasonable to deem that these compounds were produced by the fungus instead of the bacterium during the fungal-bacterial co-culture on the basis of their structures, their known fungal origins and their HPLC profiles. The α-glucosidase inhibitory effects and cytotoxicity of these isolated compounds were also estimated. The new compounds **4** and **5** revealed more potent inhibitory activity against α-glucosidase than the clinical α-glucosidase inhibitor acarbose, which allowed us to explore α-glucosidase inhibitors in lasiodiplodins.
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^1^H (400 MHz) and ^13^C (100 MHz) NMR data of **1** and **2**.

  Position   1 ^a^                       2 ^a^                                     
  ---------- --------------------------- --------------------------------- ------- ---------------------------------
  1          146.6                       7.04 (d, *J* = 9.8)               146.1   7.01 (d, *J* = 9.8)
  2          126.3                       5.84 (d, *J* = 9.8)               128.4   5.93 (d, *J* = 9.8)
  3          206.8                                                         203.4   
  4          55.0                        2.24 (q, *J* = 7.3)               54.4    2.24 (q, *J* = 6.9)
  5          39.9                                                          40.4    
  6a         34.6                        1.79 (d, *J* = 14.1)              38.9    1.87 (d, *J* = 14.0)
  6b         1.44 (d, *J* = 14.1)        1.51 (d, *J* = 14.0)                      
  7          77.8                                                          77.6    
  8          100.5                                                         100.3   
  9          135.3                       6.10 (s)                          132.2   5.94 (s)
  10         139.4                                                         142.4   
  11         43.9                        2.58 (ddq, *J* = 8.3, 7.2, 6.4)   43.9    2.54 (ddq, *J* = 7.8, 6.9, 6.4)
  12a        71.8                        4.07 (dd, *J* = 8.8, 8.3)         71.6    4.04 (dd, *J* = 8.3, 7.8)
  12b        3.34 (dd, *J* = 8.8, 6.4)   3.31 (dd, *J* = 8.3, 6.4)                 
  13         9.2                         1.01 (d, *J* = 7.2)               9.2     1.01 (d, *J* = 6.9)
  14         14.8                        0.95 (d, *J* = 7.3)               7.5     1.08 (d, *J* = 6.9)
  15         28.0                        1.35 (s)                          20.9    1.16 (s)

^a^ Measured in MeOH-*d*~4~.
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###### 

^1^H (400 MHz) and ^13^C (100 MHz) NMR data of **4**--**6**.

  Position   4 ^a^                        5 ^b^                       6 ^b^                                              
  ---------- ---------------------------- --------------------------- ------- ---------------------------------- ------- ----------------------------------
  1          172.0                                                    171.0                                      171.8   
  3          73.7                         5.37 (m)                    69.3    5.69 (ddq, *J* = 10.8, 6.3, 2.3)   74.9    5.28 (ddq, *J* = 12.8, 6.3, 3.3)
  4          31.4                         1.94 (m)                    46.1    3.31 (dd, *J* = 16.4, 10.8)        31.7    1.94 (dd, *J* = 12.8, 7.7)
  1.65 (m)   2.39 (dd, *J* = 16.4, 2.3)   1.84 (dd, *J* = 7.7, 3.3)                                                      
  5          30.2                         1.74 (m)                    210.7                                      19.2    2.08 (m)
  1.28 (m)   1.76 (m)                                                                                                    
  6          32.5                         2.12 (m)                    46.1    2.61 (m)                           38.6    2.64 (m)
  1.83 (m)   2.30 (m)                     2.55 (m)                                                                       
  7          68.0                         4.27 (m)                    21.8    2.01 (m)                           211.4   
  1.86 (m)                                                                                                               
  8          24.1                         1.92 (m)                    29.9    1.48 (m)                           42.1    2.44 (m)
  1.67 (m)   1.25 (m)                     2.35 (m)                                                                       
  9          31.1                         2.06 (m)                    30.3    1.66 (m)                           28.9    2.20 (m)
  1.76 (m)   1.57 (m)                     1.75 (m)                                                                       
  10         33.7                         3.22 (m)                    36.8    3.45 (m)                           33.6    3.14 (m)
  2.59 (m)   2.11 (m)                     2.61 (m)                                                                       
  11         148.3                                                    149.0                                      148.0   
  12         111.9                        6.74 (d, *J* = 2.4)         111.1   6.17 (d, *J* = 2.6)                110.8   6.24 (d, *J* = 2.6)
  13         163.9                                                    160.5                                      160.5   
  14         102.3                        6.84 (d, *J* = 2.4)         101.8   6.26 (d, *J* = 2.6)                102.0   6.30 (d, *J* = 2.6)
  15         164.9                                                    166.1                                      165.8   
  16         107.6                                                    104.8                                      106.0   
  17         18.2                         1.38 (d, *J* = 6.3)         19.9    1.44 (d, *J* = 6.3)                19.6    1.35 (d, *J* = 6.3)
  15-OH                                   12.42 (s)                           11.97 (s)                                  12.05(s)

^a^ Measured in pyridine-*d*~5~; ^b^ Measured in CDCl~3~.

marinedrugs-15-00035-t003_Table 3

###### 

α-Glucosidase inhibitory activities ^a^.

  Compounds   IC~50~ (µM)   Compounds      IC~50~ (µM)
  ----------- ------------- -------------- -------------
  **1**       \>200         **10**         60.3 ± 0.7
  **2**       188.7 ± 1.2   **11**         \>200
  **3**       \>200         **12**         \>200
  **4**       25.8 ± 0.2    **13**         \>200
  **5**       54.6 ± 0.5    **14**         198.1 ± 1.5
  **6**       178.5 ± 1.1   **15**         ˃200
  **7**       176.8 ± 1.4   **16**         101.3 ± 0.9
  **8**       64.2 ± 0.5    **17**         105.7 ± 1.0
  **9**       48.9 ± 0.4    Acarbose ^b^   703.8 ± 2.2

^a^ IC~50~ values are shown as mean ± SD from two independent experiments; ^b^ Positive control.
